Siddiqi Nauman, McBride Maureen A, Hariharan Sundaram
Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Kidney Int. 2004 May;65(5):1906-13. doi: 10.1111/j.1523-1755.2004.00589.x.
Renal dysfunction measured by serum creatinine (>1.5 mg/dL) at 1 year post-transplant correlates with long-term kidney graft survival. The purpose of this study was to compare the risk factors for elevated serum creatinine (SCr) >1.5 mg/dL at 1 year post-transplantation, and for long-term graft failure.
Between 1988 and 1999, 117,501 adult kidney transplants were reported to Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS). Of these, 96,091 were functioning at 1 year and SCr was available on 85,135 transplants. Donor and recipient demographics (age, sex, and race), transplant [living vs. cadaveric, previous transplantation, panel reactive antibody (PRA), human leukoocyte antigen (HLA) mismatch, cold ischemic time (CIT) and post-transplant delayed graft function (DGF), use of azathioprone vs. mycophenolate mofetil (MMF), cyclosporine A (CsA) vs. tacrolimus (Tac)], induction antibody, acute rejection within 1 year variables were used in the logistic regression model to estimate odds ratio (OR) for elevated 1 year serum creatinine (SCr). A Cox proportional hazard model was used to estimate the relative risk (RR) for long-term kidney graft failure with and without censoring for death with a functioning graft.
Five-year actuarial graft survival for living donor transplant with SCr >1.5 and </=1.5 mg/dL at 1 year post-transplant was 83% and 88.6% (P < 0.001). The corresponding values for cadaveric transplant grafts were 66.5% and 77.9% (P < 0.001). The overall prevalence of renal dysfunction at 1 year post-transplant (SCr >1.5 mg/dL) declined from 54.5% in 1988 to 42.3% in 1999. There was a strong concordance between the key variables, such as cadaveric transplant, increasing CIT, HLA mismatch, DGF, and acute rejection, recipient race (black), younger age, and nondiabetics status; and donor race (black) and older age for elevated SCr and long-term graft failure.
Donor (age), race (black), recipient race (black), immunologic variables (HLA mismatch, DGF, acute rejection) were identified as important risk factors for elevated SCr at 1 year post-transplantation and long-term graft failure. Elevated SCr should be used as a short-term marker for predicting long-term transplant survival.
移植后1年时通过血清肌酐(>1.5mg/dL)测定的肾功能不全与长期肾移植存活相关。本研究的目的是比较移植后1年时血清肌酐(SCr)>1.5mg/dL升高以及长期移植失败的危险因素。
1988年至1999年间,向器官获取与移植网络/器官共享联合网络(OPTN/UNOS)报告了117,501例成人肾移植。其中,96,091例在1年时仍有功能,85,135例移植受者有血清肌酐数据。供体和受体的人口统计学特征(年龄、性别和种族)、移植情况[活体与尸体供肾、既往移植史、群体反应性抗体(PRA)、人类白细胞抗原(HLA)错配、冷缺血时间(CIT)和移植后延迟性移植物功能(DGF)、硫唑嘌呤与霉酚酸酯(MMF)的使用、环孢素A(CsA)与他克莫司(Tac)]、诱导抗体、1年内急性排斥反应等变量用于逻辑回归模型,以估计移植后1年血清肌酐(SCr)升高的比值比(OR)。采用Cox比例风险模型估计长期肾移植失败的相对风险(RR),并对有功能移植物的死亡进行删失分析。
移植后1年血清肌酐>1.5mg/dL和≤1.5mg/dL的活体供肾移植5年预期移植存活率分别为83%和88.6%(P<0.001)。尸体供肾移植的相应数值分别为66.5%和77.9%(P<0.001)。移植后1年肾功能不全(SCr>1.5mg/dL)的总体患病率从1988年的54.5%降至1999年的42.3%。尸体供肾移植、CIT增加、HLA错配、DGF、急性排斥反应、受体种族(黑人)、年龄较小和非糖尿病状态等关键变量;以及供体种族(黑人)和年龄较大与SCr升高和长期移植失败之间存在很强的一致性。
供体(年龄)、种族(黑人)、受体种族(黑人)、免疫变量(HLA错配、DGF、急性排斥反应)被确定为移植后1年时SCr升高和长期移植失败的重要危险因素。SCr升高应作为预测长期移植存活的短期指标。